Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Brain-derived neurotrophic factor as a biomarker in primary open-angle glaucoma.

Authors: Ghaffariyeh, A  Honarpisheh, N  Heidari, MH  Puyan, S  Abasov, F 
Citation: Ghaffariyeh A, etal., Optom Vis Sci. 2011 Jan;88(1):80-5. doi: 10.1097/OPX.0b013e3181fc329f.
Pubmed: (View Article at PubMed) PMID:21076359
DOI: Full-text: DOI:10.1097/OPX.0b013e3181fc329f

PURPOSE: To introduce a novel biomarker for screening of primary open-angle glaucoma (POAG) by detecting and measuring brain-derived neurotrophic factor (BDNF) in the serum of normal subjects and patients with early stage of glaucoma. METHODS: Twenty-five glaucoma patients as the case group and 25 age- and sex-matched normal persons as the control group were tested. The control group comprised 19 men and 6 women, with the mean age of 59.32 +/- 11.8 years and without any apparent ocular or systemic diseases. The case group comprised 20 men and 5 women, with the mean age of 59.64 +/- 11.56 years, who were assessed by routinely performed clinical and paraclinical investigations. BDNF levels in serum were determined by enzyme-linked immunosorbent assay using monoclonal antibodies specific for BDNF. RESULTS: The mean of BDNF levels in the serum was 27.16 +/- 5.53 ng/mL in the control subjects and 18.42 +/- 4.05 ng/mL in the subjects with the early stage glaucoma. A statistically significant difference was evident between the two groups (p < 0.05). We found no significant differences in serum BDNF levels according to the subjects' age, gender, duration of the glaucoma, mean intraocular pressure, and blood pressure (p > 0.05). Glaucoma patients who had lower serum BDNF concentration had disclosed a significant negative correlation with pattern standard deviations. CONCLUSIONS: We conclude that BDNF in the serum might be a useful biochemical marker for early detection of POAG. We also propose that this might be a reliable, time efficient, and cost-effective method for diagnosis, screening, and assessing the progression of POAG. However, more studies and trials are needed to investigate these factors in greater detail.

Annotation

Disease Annotations
Gene Ontology Annotations
Objects Annotated

Additional Information

 
RGD Object Information
RGD ID: 8655612
Created: 2014-05-20
Species: All species
Last Modified: 2014-05-20
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.